AlgiPharma AS

AlgiPharma AS – A biopharmaceutical company with a primary focus on developing its first drug candidate for patients with Cystic Fibrosis.

A Better Day

AlgiPharma AS is a clinical stage biopharmaceutical company with a primary focus on respiratory diseases and other conditions caused by microbial infections and biofilms. Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance.

AlgiPharma’s OligoG technology is based on highly purified and defined oligomer saccharide structures.

Technology

The predicted median age of survival is steadily improving for CF patients and today is close to 40.

Products

AlgiPharma AS is dedicated to the development and commercialisation of novel therapeutics that will help transform the lives of patients with chronic diseases: Helping patients and their families towards a better day.

AlgiPharma has successfully completed a Phase 2a clinical trial and a drug deposition study in Cystic Fibrosis. The drug candidate has proven to be safe and well tolerated.

About us

AlgiPharma have multiple formulations in use and under development for inhalation, oral, and topical administration for the treatment of respiratory diseases and microbial infections.